#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Michael Hayden Email
CEO . Prilenia Therapeutics
Herzliya,
LocationPrimary Email
How to contact Michael Hayden
Join and see Michael's contact info for free!Current Roles
Employees:
39Revenue:
$6MAbout
Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. The company is led by Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018. Our lead asset is Pridopidine, a first-in-class drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for the treatment of Huntington's disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.Prilenia Therapeutics Address
N/AHerzliya, null
Israel